Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Other Accumulated Expenses (2017 - 2025)

Sonoma Pharmaceuticals has reported Other Accumulated Expenses over the past 11 years, most recently at $487000.0 for Q1 2025.

  • For Q1 2025, Other Accumulated Expenses fell 29.83% year-over-year to $487000.0; the TTM value through Mar 2025 reached $487000.0, down 29.83%, while the annual FY2025 figure was $487000.0, 29.83% down from the prior year.
  • Other Accumulated Expenses for Q1 2025 was $487000.0 at Sonoma Pharmaceuticals, down from $694000.0 in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $784000.0 in Q1 2022 and troughed at $367000.0 in Q1 2021.
  • A 5-year average of $579600.0 and a median of $566000.0 in 2023 define the central range for Other Accumulated Expenses.
  • Biggest five-year swings in Other Accumulated Expenses: soared 113.62% in 2022 and later decreased 29.83% in 2025.
  • Year by year, Other Accumulated Expenses stood at $367000.0 in 2021, then soared by 113.62% to $784000.0 in 2022, then dropped by 27.81% to $566000.0 in 2023, then increased by 22.61% to $694000.0 in 2024, then decreased by 29.83% to $487000.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for SNOA at $487000.0 in Q1 2025, $694000.0 in Q1 2024, and $566000.0 in Q1 2023.